Source: Abstracts. Conference titles: Annual Congress of the European Hematology Association (EHA). Unidade: FCF
Subjects: POLIMORFISMO, LEUCEMIA MIELOIDE
ABNT
GUERRA-SHINOHARA, Elvira Maria et al. SLC22A1 polymorphisms are not associated with cytogenetic and molecular response to imatinib mesylate in chronic myelogenous leukemia patients. 2011, Anais.. Hague: European Hematology Association (EHA), 2011. . Acesso em: 28 out. 2024.APA
Guerra-Shinohara, E. M., Bueno, C. T., Lima, L. T. de, Vivona, D., Hirata, R. D. C., Hirata, M. H., et al. (2011). SLC22A1 polymorphisms are not associated with cytogenetic and molecular response to imatinib mesylate in chronic myelogenous leukemia patients. In Abstracts. Hague: European Hematology Association (EHA).NLM
Guerra-Shinohara EM, Bueno CT, Lima LT de, Vivona D, Hirata RDC, Hirata MH, Luchessi AD, Chiattone CS, Zanichelli MA. SLC22A1 polymorphisms are not associated with cytogenetic and molecular response to imatinib mesylate in chronic myelogenous leukemia patients. Abstracts. 2011 ;[citado 2024 out. 28 ]Vancouver
Guerra-Shinohara EM, Bueno CT, Lima LT de, Vivona D, Hirata RDC, Hirata MH, Luchessi AD, Chiattone CS, Zanichelli MA. SLC22A1 polymorphisms are not associated with cytogenetic and molecular response to imatinib mesylate in chronic myelogenous leukemia patients. Abstracts. 2011 ;[citado 2024 out. 28 ]